An Alzheimer’s Drug Was Supposed to Be a Blockbuster for Biogen. Its Failure Cost the CEO His Job.
The controversial Alzheimer's drug, Aduhelm, was approved by the FDA without strong evidence it worked. Now its failure has cost Biogen CEO Michel Vounatsos his job.